English
Spanish
French
German
Italian
Dutch
Russian
Chinese (Simplified)
Japanese
Hindi
Hebrew
Portuguese
by June Kinoshita, FSHD Society Over the next 12 to 24 months, four clinical trials for FSH muscular dystrophy are expected to launch. All of these upcoming trials all target… Read More »
What we started…
Fulcrum’s Phase 3 trial news – what does it mean for patients?
by June Kinoshita, Director of Research and Patient Engagement Fulcrum’s announcement that it will proceed with a Phase 3 clinical trial of losmapimod is big news for the FSHD community…. Read More »
Fulcrum announces Phase 3 trial of losmapimod
From Fulcrum Therapeutics’ press release Reachable Workspace (RWS) primary endpoint based on discussions with FDA and EU regulatory agencies Trial expected to begin in 2Q 2022 Potential first-to-market therapy for… Read More »
Teen with FSHD is in top 40 of Science Talent Search
Our very own Heloise Hoffmann, leader of the Southwest Florida chapter and Walk & Roll, is a science rock star! The Society for Science named her a top 40 finalist… Read More »
FSHD Canada Foundation awards $2.8 million to CTRN
by June Kinoshita, FSHD Society The FSHD Canada Foundation, a close partner and fellow traveler of the FSHD Society since its founders Neil Camarta and Craig Kelley first met in… Read More »